

## **EISAI SUBMITS APPLICATION TO EXPAND INDICATION OF ANTI-ALZHEIMER'S AGENT ARICEPT<sup>®</sup> AS TREATMENT FOR DEMENTIA WITH LEWY BODIES IN JAPAN**

Eisai Co., Ltd. (Headquarters: Tokyo, President **BAOUI Pa [ Á aá] ÉOã aáDa** } &^ãÁ áæ Á@) it has filed an application for the anti-Alzheimer's agent Aricept<sup>®</sup> (donepezil hydrochloride, %donepezil+) in Japan, requesting a new indication expansion to use the agent in the treatment of dementia with Lewy bodies (DLB).

DLB

**[Notes to editors]**

**1. About Dementia with Lewy Bodies (DLB)**

DLB is a degenerative form of dementia that is pathologically characterized by decreased neurons in the brain and brainstem and the appearance of vast numbers of Lewy bodies. In neurochemistry, DLB is characterized by a loss of acetylcholine-producing neurons in the brain similar to that seen in patients with Alzheimer's disease, although the extent of this loss is reportedly greater in patients with DLB. In addition to obligatory symptoms associated with progressive cognitive impairment, the disease also presents with behavioral and neuropsychiatric symptoms, motor disturbances, a

the placebo group, 1.4 points in the 5 mg group and 2.2